Skip to content
value.today

CytRx Corp. is listed today as CytRx Corporation: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of CytRx Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2021$8 MPrivate placement after listing$2 to $10 million

CytRx Corp.: Private sale, Jul 2021

Investors in this round

1 investor had bought by the notice of Jul 28, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $18 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$1,281,600
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Caloz · Executive Officer · Chief Financial Officer
  • Stephen Snowdy · Executive Officer · Chairman and Chief Executive Officer
  • Cary Claiborne · Director
  • Jennifer Simpson · Director
  • Joel Caldwell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Consists of: $600,000 cash fee (6% of the aggregate gross proceeds), $75,000 in reimbursable non-accountable expenses, $6,600 in escrow fees and $600,000, the maximum additional cash fee payable to the Agent, subject to the exercise of PIOs for cash.”
  • On the amounts: “"Represents 8,240 shares of Series C 10.00% Convertible Preferred Stock at $1,000 per share and preferred investment options (""PIOs"") to purchase up to 11,363,637 shares of common stock, exercise price of $0.88 per share, initially sold on 7/13/2021."”

Signed by John Caloz, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 28, 2022. Read the notice at the SEC.

equity, optionsSEC
Feb 2016$1 MPrivate placement after listingUnder $2 million

CytRx Corp.: Private sale, Feb 2016

Investors in this round

2 investors had bought by the notice of Feb 10, 2016: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 505: the former limited-offering exemption (withdrawn in 2017)
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin Levin · Executive Officer
  • John Caloz · Executive Officer
  • Steven Kreigsman · Executive Officer, Director
  • d Haen · Executive Officer
  • Anita Chawla · Director
  • Cheryl Cohen · Director
  • Eric Selter · Director
  • Joseph Rubinfeld · Director
  • Louis Ignarro · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The securities sold consisted of warrants to purchase up to 630,000 shares of the issuer's common stock at an exercise price of $2.05 per share, or a total exercise price of $1,291,500.”

Signed by John Caloz, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 10, 2016. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CytRx Corp. chose not to state its revenue in its newest notice of a funding round (Jul 2022).

    SEC Form D · Jul 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2022

That is all the official record says: CytRx Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of CytRx Corp. are on record.

Investors#

No investor of CytRx Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CytRx Corp.
NameRoleNamed in
John CalozChief Financial OfficerJul 2022
Stephen SnowdyChairman and Chief Executive OfficerJul 2022
Steven A KriegsmanChairman and Chief Executive OfficerJul 2021
Benjamin LevinExecutive officerFeb 2016
Steven KreigsmanExecutive officerFeb 2016
d HaenExecutive officerFeb 2016
Cary ClaiborneDirectorJul 2022
Jennifer SimpsonDirectorJul 2022
Joel CaldwellDirectorJul 2022
Joel J CaldwellDirectorJul 2021
Louis J IgnarroDirectorJul 2021
Steven A KriegsmanChairman and Chief Executive OfficerJul 2021
Anita ChawlaDirectorFeb 2016
Cheryl CohenDirectorFeb 2016
Eric SelterDirectorFeb 2016
Joseph RubinfeldDirectorFeb 2016
Louis IgnarroDirectorFeb 2016
Steven KreigsmanDirectorFeb 2016

About

Biopharmaceutical research company in Los Angeles, California, USA.

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.